Why a $3.5 Million Bet Targets Avantor Amid a 54% Stock Drop

Circumference Group disclosed a new 13F position in Avantor, acquiring 305,000 shares (~$3.5M), representing 3.77% of its reported AUM as of 12/31/25. Avantor trades at $7.51, down ~54% over the past year; company metrics include TTM revenue $6.55B, net loss ($530.2M), market cap ~$5.1B, adjusted EBITDA >$1B and free cash flow near $500M. The purchase signals selective institutional interest despite weak profitability and a steep share-price decline; recovery depends on execution of management’s 'Revival' program to restore margins and operational performance.

Analysis

Avantor’s situation is a classic operational-turnaround opportunity where durable end-market demand (lab consumables, biopharma production inputs) decouples from headline profitability—meaning the key value-inflection is execution of margin restoration rather than top-line growth. If management can convert a modest percentage of adjusted EBITDA into free cash flow through pricing discipline, SKU rationalization and procurement savings, equity upside will be front-loaded as leverage unwinds and multiple compression reverses.

Second-order winners from a successful “Revival” execution are specialist service and software providers: outsourced restructuring/operations consultancies and lab informatics vendors should see incremental project flow and longer-term contracts as Avantor delegates non-core functions. Conversely, near-term loser scenarios include smaller specialized chemical suppliers if Avantor uses its scale to rebid contracts aggressively; price-led share grabs would compress specialty margins across the value chain.

Primary risks are execution and cadence: missed quarterly milestones, working-capital volatility, or a weak pharma capex cycle could keep capital markets skeptical for multiple quarters and push valuation lower; conversely, a clean two-quarter run of FCF beats or a credible multi-quarter run-rate disclosure would likely trigger a step-change rerating. Watch for near-term catalysts (quarterly FCF cadence, detailed run-rate savings disclosure, or a strategic asset-sale announcement) that could crystallize a >3-6 month recovery path.

Key Decisions for Investors

• Small, structured long in AVTR — buy a 9–12 month call spread (long nearer-term ATM call, sell a further OTM call) sized 1–2% of portfolio. Rationale: asymmetric upside if cost-out cadence shows repeatability; capped downside through the spread limits drawdown to premium paid. Timeframe: 6–12 months; target >2x payoff if sequential adjusted EBITDA/FCF prints beat.
• Hedgeable equity exposure — accumulate a tactical long AVTR position (max 2–3% portfolio) only when accompanied by put protection (buy 6-month OTM puts ~15–25% OTM) to limit tail risk. Use this into the next two quarterly reports; exit if a) two sequential misses occur or b) management fails to detail sustainable run-rate savings within 12 months.
• Credit-sensitive play — purchase AVTR senior unsecured bonds or near-term maturities if spread to investment-grade benchmarks remains wide (look for spreads >250bps over benchmark). Timeframe: 1–3 years; reward is carry plus upside recovery; risk is credit deterioration—trim on signs of covenant breaches or deteriorating liquidity.
• Pair trade for restructuring exposure — long RGP (consulting exposure) vs modest short of a large, premium lab-supplier stock if available. Rationale: outsourcing of transformation work benefits consultancies faster than large-cap suppliers; timeframe 3–9 months to capture project ramp; risk: broad capex tailwinds that re-rate large suppliers instead.